MyFinsight
Home
Blog
About
Proceeds from exercise of
common stock options...
$217K
(358.33%↑ Y/Y)
Net cash provided by
(used in) financing...
$217K
(358.33%↑ Y/Y)
Net (decrease)
increase in cash and cash...
-$10,875K
(-68.89%↓ Y/Y)
Canceled cashflow
$217K
Accrued expenses and
other current...
$2,874K
(640.23%↑ Y/Y)
Stock-based compensation
expense
$1,511K
(-56.54%↓ Y/Y)
Noncash rent expense
$550K
(-64.49%↓ Y/Y)
Depreciation expense
$28K
(-83.82%↓ Y/Y)
Proceeds from sales and
maturities of investments
$15,000K
(-76.03%↓ Y/Y)
Net cash provided by
(used in) operating...
-$7,968K
(-118.01%↓ Y/Y)
Net cash provided by
(used in) investing...
-$3,124K
(93.83%↑ Y/Y)
Canceled cashflow
$4,963K
Canceled cashflow
$15,000K
Net income (loss)
-$9,905K
(-121.54%↓ Y/Y)
Purchases of investments
$18,124K
(-83.99%↓ Y/Y)
Accounts payable
-$1,565K
(51.64%↑ Y/Y)
Non-current operating lease
liabilities
-$993K
(45.20%↑ Y/Y)
Other non-current
assets
$256K
(390.91%↑ Y/Y)
(accretion) amortization on
investments
$170K
(-79.71%↓ Y/Y)
Prepaid expenses and
other current assets
$42K
(-92.67%↓ Y/Y)
Back
Back
Cash Flow
Black Diamond Therapeutics, Inc. (BDTX)
Black Diamond Therapeutics, Inc. (BDTX)
source: myfinsight.com